Elite Pharmaceuticals Statistics
Want to see ELTP full AI Analyst Report?
Elite Pharmaceuticals (ELTP) Stock Statistics & Valuation Metrics
Total Valuation
Elite Pharmaceuticals has a market cap or net worth of $349.02M. The enterprise value is $242.02M.
- Market Cap
- $349.02M
- Enterprise Value
- $242.02M
Share Statistics
Elite Pharmaceuticals has 1,077,569,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,077,569,800
- Owned by Insiders
- 0.87%
- Owned by Institutions
- <0.01%
Financial Efficiency
Elite Pharmaceuticals’s return on equity (ROE) is 0.45 and return on invested capital (ROIC) is 32.33%.
- Return on Equity (ROE)
- 0.45
- Return on Assets (ROA)
- 0.32
- Return on Invested Capital (ROIC)
- 32.33%
- Return on Capital Employed (ROCE)
- 0.41
- Revenue Per Employee
- 2.29M
- Profits Per Employee
- 690.35K
- Employee Count
- 65
- Asset Turnover
- 1.08
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Elite Pharmaceuticals is 5.68. Elite Pharmaceuticals’s PEG ratio is 0.01.
- PE Ratio
- 5.68
- PS Ratio
- 2.37
- PB Ratio
- 2.81
- Price to FCF
- 39.35
- Price to Operating Cash Flow
- 31.58
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Elite Pharmaceuticals had revenue of 148.87M and earned 44.87M in profits. Earnings per share was 0.04.
- Revenue
- 148.87M
- Gross Profit
- 73.48M
- Operating Income
- 49.96M
- Pretax Income
- 56.81M
- Net Income
- 44.87M
- EBITDA
- 51.98M
- Earnings Per Share (EPS)
- 0.04
Cash Flow
In the last 12 months, operating cash flow was 10.86M and capital expenditures -2.15M, giving a free cash flow of 8.72M billion.
- Operating Cash Flow
- 10.86M
- Free Cash Flow
- 8.72M
- Free Cash Flow per Share
- 0.01
Dividends & Yields
Elite Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.51%
- Earnings Yield
- 17.38%
Stock Price Statistics
- Beta
- 1.51
- 52-Week Price Change
- -44.12%
- 50-Day Moving Average
- 0.25
- 200-Day Moving Average
- 0.34
- Relative Strength Index (RSI)
- 62.96
- Average Volume (3m)
- 836.61K
Important Dates
Elite Pharmaceuticals upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Elite Pharmaceuticals as a current ratio of 6.45, with Debt / Equity ratio of 5.88%
- Current Ratio
- 6.45
- Quick Ratio
- -1215.99
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -573.16
- Interest Coverage Ratio
- 125.95
Taxes
In the past 12 months, Elite Pharmaceuticals has paid 11.94M in taxes.
- Income Tax
- 11.94M
- Effective Tax Rate
- 0.21
Enterprise Valuation
Elite Pharmaceuticals EV to EBITDA ratio is 8.03, with an EV/FCF ratio of 36.38.
- EV to Sales
- 2.19
- EV to EBITDA
- 8.03
- EV to Free Cash Flow
- 36.38
- EV to Operating Cash Flow
- 29.20
Balance Sheet
Elite Pharmaceuticals has $34.86M in cash and marketable securities with $5.18M in debt, giving a net cash position of $29.68M billion.
- Cash & Marketable Securities
- $34.86M
- Total Debt
- $5.18M
- Net Cash
- $29.68M
- Net Cash Per Share
- $0.03
- Tangible Book Value Per Share
- $0.11
Margins
Gross margin is 43.41%, with operating margin of 25.90%, and net profit margin of 41.64%.
- Gross Margin
- 43.41%
- Operating Margin
- 25.90%
- Pretax Margin
- 47.76%
- Net Profit Margin
- 41.64%
- EBITDA Margin
- 27.29%
- EBIT Margin
- 25.90%
Analyst Forecast
The average price target for Elite Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 17.81%
- EPS Growth Forecast
- 331.54%
Scores
- Smart Score
- 4
- AI Score
- 77

